Clinic bills set to soar: Doctors warn of 30pct hike under new pricing rule
The Federation of Private Medical Practitioners' Associations Malaysia (FPMPAM) said that patients would bear the brunt of the cost increase, as clinics were now required to itemise charges that were previously bundled under a single fee.
Its president Dr Shanmuganathan T.V. Ganeson said that the new rule disrupted the existing billing system, in which consultation, treatment, and medication were charged together.
"Clinics now have to unbundle costs, including operating expenses, which must be separately listed on the bill," said Dr Shanmuganathan.
According to Utusan Malaysia, estimates suggest that patient charges could rise by between 10 and 30 per cent, depending on the type of treatment and medication. In some cases, a standard consultation may cost RM10 to RM30 more than before.
On May 6, some 200 doctors gathered at Laman Perdana near Perdana Putra in Putrajaya to protest the new directive.
The group assembled at 9.30am before a 10-member delegation, led by Malaysian Medical Association (MMA) representative Datuk Dr R. Thirunavukarasu, entered the Prime Minister's Office to submit a memorandum.
The protesters urged the government to review Act 723 and place regulation of medical practice solely under the Private Healthcare Facilities and Services Act 1998 (Act 586), which they argued was sufficient for the sector.
While protests continue, most private clinics have already begun displaying medicine prices, as required. Bundled billing remains in place at many clinics for the time being, pending a decision from the Health Ministry.
Patients may begin to see higher bills as early as August if no changes are introduced during the grace period.
"Once the grace period ends, clinics will be required to provide a full breakdown of all charges," Dr Shanmuganathan said.
The price display requirement, gazetted on May 1, falls under the Price Control and Anti-Profiteering Act 2011 (Act 723) and is enforced by the Domestic Trade and Cost of Living Ministry. It applies to all private clinics, hospitals, and pharmacies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
2 days ago
- Barnama
MBSB IB Maintains Positive Call On Insurance Sector Despite Healthcare Inflation
-- Photograph for illustrative purposes MBSB IB Maintains Positive Call On Insurance Sector Despite Healthcare Inflation KUALA LUMPUR, Aug 15 (Bernama) -- MBSB Investment Bank (MBSB IB) has maintained its 'positive' recommendation on the insurance sector, citing attractive valuations and high dividend yields despite persistent healthcare inflation and delays in healthcare cost-control reforms. In a research note today, the bank said healthcare inflation remains a 'tricky issue to fix' as higher spending on the sector appears inevitable. 'Our primary concern is that if healthcare inflation is still rampant, what will happen at the end of Bank Negara Malaysia's three-year cap on medical insurance premium hikes? 'But there are multiple tailwinds -- a cheap price point, attractive dividend yields, a potential windfall in investment income, and encouraging progress by insurers in addressing the healthcare inflation problem -- making the sector due for a positive re-rating,' it said. The bank noted that companies under its coverage are market leaders, enabling them to withstand challenges better than most. MBSB IB said medical cost pressures are being fuelled by private hospitals rejecting proposed cost freezes, opposing pharmaceutical price controls, and what insurers describe as 'buffet table syndrome', where high claims are linked to increased service use without clear medical need. It also pointed to Malaysia's relatively low preventive healthcare spending and intensifying competition in healthcare tourism from Thailand, Indonesia and Singapore. However, the bank highlighted some progress in tackling medical inflation, including the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025, which will require mandatory medicine price displays in the private sector by 2026. 'The initiative aims to enable the public to make informed choices by knowing the prices in advance and to encourage competitive medical pricing, although it has faced resistance, with several medical groups filing a judicial review," it said. The bank added that another factor is the decline in active pharmaceutical ingredient (API) raw material prices to pre-pandemic levels, after surging during the pandemic and staying elevated for several years due to logistical constraints, factory closures and increased demand for healthcare products. MBSB IB's top picks are Allianz Malaysia Bhd, with a target price of RM21.59, and Syarikat Takaful Malaysia Keluarga Bhd, with a target price of RM4.59, while LPI Capital Bhd is also rated 'buy'. -- BERNAMA
BusinessToday
2 days ago
- BusinessToday
Insurance Sector Poised For Healthy Gain Despite Inflation Worries
MBSB Investment Bank Bhd (MBSB Research) has maintained a POSITIVE call on the insurance sector, citing attractive valuations, solid dividend yields, and signs of progress in tackling healthcare inflation despite persistent headwinds. Allianz and Syarikat Takaful Malaysia Bhd (STMB) remain top picks with 'buy' recommendations and target prices of RM21.59 and RM4.59, respectively. The optimism comes even as the government once again postponed the mandatory rollout of the diagnosis-related groups (DRG) payment system for private hospitals, pushing the implementation from mid-2025 to 2027. The DRG framework, widely used in countries such as Thailand and Indonesia, aims to standardise hospital reimbursement based on diagnosis and treatment rather than charging per service. An interim version will begin in selected private hospitals this year, alongside a basic Medical and Health Takaful Insurance platform scheduled for 2026. Insurers have been taking firmer steps to address medical cost inflation, though MBSB noted that increased healthcare spending remains unavoidable. Malaysia's healthcare tourism industry is under competitive pressure from regional players such as Thailand and Singapore, with private hospitals investing heavily in high-end facilities to attract overseas patients. The Association of Private Hospitals Malaysia (APHM) has pushed back against several insurer proposals, including freezing private hospital costs for three years and regulating pharmaceutical prices, arguing these could compromise care standards and limit access to new treatments. Rising claims have also been attributed by APHM to more severe patient cases, potentially linked to post-pandemic complications. Preventive care remains a weak spot, with just 6–7% of the Health Ministry's budget allocated to prevention, far below the treatment allocation. Still, MBSB highlighted recent progress. The Price Control and Anti-Profiteering Order 2025 will require private sector medicine price displays by 2026, promoting transparency and competition. The cost of active pharmaceutical ingredients has also retreated to pre-pandemic levels, easing some pressure on drug prices. Furthermore, co-pay uptake is gaining traction, with Allianz reporting encouraging adoption rates and insurers seeing lower health loss ratios in early 2025. MBSB Research emphasised that while healthcare inflation is unlikely to disappear, continued insurer initiatives, combined with a low sector price point and the potential for higher investment income, provide a case for a positive re-rating. The firm noted that companies under its coverage are market leaders, better positioned to navigate economic uncertainty and the structural challenges of rising reinsurance costs. However, risks remain, including the possibility of slower premium growth if the economy weakens and the threat of persistent healthcare inflation even after the DRG rollout.
Malaysian Reserve
2 days ago
- Malaysian Reserve
Zara Qairina's mother 'not thinking clearly' after daughter's death
MOTHER of late Zara Qairina Mahathir has admitted that she was not thinking clearly when asked to decide on allowing a post-mortem on her daughter's body. As reported by Utusan Malaysia today, Noraidah Lamat said she experienced shock and confusion after her daughter's death, which left her unable to grasp the procedure as no one provided her with a clear explanation. In a Facebook post under the name Noie AiDa, she stated that had she understood, she would never have refused the post-mortem. 'Can you imagine our situation now? Her death happened so suddenly — just one night at Queen Elizabeth Hospital (HQE), 20 hours after being admitted to the Neuro Ward,' she wrote. Her lawyer Hamid Ismail confirmed that the account belonged to Noraidah. Meanwhile, Bukit Aman Criminal Investigation Department (CID) director Datuk M Kumar revealed that a task force investigation which began last Monday revealed procedural breaches. The investigating officer had failed to request a post-mortem on Zara Qairina's body. He stated that stern action will be taken against the officer and their supervisor for failing to provide proper oversight. However, Kumar noted that the victim's mother had provided written consent to forgo the post-mortem which is documented in a 'Declaration of Refusal for Post-mortem on Own Request' issued by the hospital. It was signed by the mother, doctor, pathologist and investigating officer. Meanwhile, the Sabah Law Society (SLS) said the Attorney General's Chambers' (AGC) decision to hold an inquest into Zara Qairina's death is an important step toward uncovering the truth and ensuring accountability. SLS president Datuk Mohamed Nazim Maduarin welcomed the move and said the society will closely follow the inquest and any related legal proceedings in the public interest. 'We stand ready to engage with relevant stakeholders in Sabah to ensure that this tragedy leads to meaningful reforms in safeguarding children from harm,' he said in a statement.
